Source briefingSeptember 29, 2026Health & Science

From wrist to research: Harnessing smartwatch data for equitable cardiovascular research

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Manpreet Kaur, on behalf of the PLOS Medicine Staff Editors Cardiovascular disease is a leading cause of death, and progress in reducing mortality has stalled, calling for more research. An opportunity lies in harnessing cardiovascular data from smartwatches. However, ethical and logistical barriers need to be overcome to ensure smartwatch-derived data is utilised to inform equitable and actionable cardiovascular research.

Cardiovascular disease is a leading cause of death, and progress in reducing mortality has stalled, calling for more research. In this…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · September 28, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EMA/PE/0000181364

What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795

Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…

EMA/PE/0000261344

Evidence Dossier: EMA Decision on Colchicine Paediatric Investigation Plan (PIP) What is established On 8 August 2025, the European Medicines Agency (EMA) granted a…